KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesR&D In ProcessReceivables - NetReceivables - Other
Ratios

Eli Lilly (LLY) R&D In Process (2016 - 2025)

Eli Lilly's R&D In Process history spans 16 years, with the latest figure at $520.0 million for Q4 2025.

  • For Q4 2025, R&D In Process rose 147.62% year-over-year to $520.0 million; the TTM value through Dec 2025 reached $2.9 billion, down 12.17%, while the annual FY2025 figure was $2.9 billion, 12.12% down from the prior year.
  • R&D In Process reached $520.0 million in Q4 2025 per LLY's latest filing, down from $655.7 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $3.0 billion in Q3 2023 to a low of $25.0 million in Q2 2021.
  • Average R&D In Process over 5 years is $594.0 million, with a median of $225.0 million recorded in 2022.
  • The largest YoY upside for R&D In Process was 4667.79% in 2023 against a maximum downside of 77.95% in 2023.
  • A 5-year view of R&D In Process shows it stood at $471.8 million in 2021, then tumbled by 49.11% to $240.1 million in 2022, then skyrocketed by 159.39% to $622.8 million in 2023, then plummeted by 66.28% to $210.0 million in 2024, then skyrocketed by 147.62% to $520.0 million in 2025.
  • Per Business Quant, the three most recent readings for LLY's R&D In Process are $520.0 million (Q4 2025), $655.7 million (Q3 2025), and $153.8 million (Q2 2025).